Literature DB >> 7125684

Phenobarbitone dosage in neonatal convulsions.

R A Ouvrier, R Goldsmith.   

Abstract

In order to find the optimal dosage schedule of phenobarbitone for neonatal convulsions, four groups of patients were studied. Twelve infants (group 1) received a mean phenobarbitone dose of 9.5 mg/kg a day given intramuscularly for 3 days followed by 5.8 mg/kg a day given intramuscularly and then orally. Six infants (group 2) received a mean intravenous loading dose of 9.5 mg/kg followed by 6.8 mg/kg a day given intramuscularly or orally. Nine infants (group 3) received a mean loading dose of 14.9 mg/kg intravenously followed by a maintenance dose of 5.9 mg/kg a day. Thirteen patients (group 4) received a mean intramuscular loading dose of 15.2 mg/kg followed by 5.9 mg/kg a day. Blood samples were taken regularly and phenobarbitone levels were determined by gas liquid chromatography. A mean intravenous or intramuscular loading dose of 15 mg/kg of phenobarbitone safely achieved therapeutic levels within 2 hours of injection and high therapeutic levels were maintained with a dose of 6 mg/kg a day.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7125684      PMCID: PMC1627799          DOI: 10.1136/adc.57.9.653

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  13 in total

1.  Epileptic brain damage in adolescent baboons following seizures induced by allylgycine.

Authors:  B S Meldrum; R W Horton; J B Brierley
Journal:  Brain       Date:  1974-06       Impact factor: 13.501

2.  A study of clinical, pathological, and electroencephalographic features in 137 full-term babies with a long-term follow-up.

Authors:  A L Rose; C T Lombroso
Journal:  Pediatrics       Date:  1970-03       Impact factor: 7.124

3.  Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.

Authors:  M Ehrnebo; S Agurell; B Jalling; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

4.  Phenobarbitone dosage in the neonate--preliminary communication.

Authors:  R A Ouvrier; R Goldsmith
Journal:  Clin Exp Neurol       Date:  1977

5.  [Pharmacokinetic data on phenobarbital. Study on the influence of gestational age and dysmaturity].

Authors:  R J Royer; P Vert; J M Mur; J C Pladys; F Humbert; M J Royer-Morrot
Journal:  Arch Fr Pediatr       Date:  1976-11

6.  Plasma concentrations of phenobarbital in the treatment of seizures in newborns.

Authors:  B Jalling
Journal:  Acta Paediatr Scand       Date:  1975-05

7.  Phenobarbital metabolism in adults and in newborn infants.

Authors:  L O Boréus; B Jalling; N Kållberg
Journal:  Acta Paediatr Scand       Date:  1978-03

8.  Phenobarbital pharmacokinetics in neonates.

Authors:  W Pitlick; M Painter; C Pippenger
Journal:  Clin Pharmacol Ther       Date:  1978-03       Impact factor: 6.875

9.  Phenobarbital and diphenylhydantoin levels in neonates with seizures.

Authors:  M J Painter; C Pippenger; H MacDonald; W Pitlick
Journal:  J Pediatr       Date:  1978-02       Impact factor: 4.406

10.  Convulsive status epilepticus in infants and children. A study of 239 cases.

Authors:  J Aicardi; J J Chevrie
Journal:  Epilepsia       Date:  1970-06       Impact factor: 5.864

View more
  3 in total

1.  Brief postnatal exposure to phenobarbital impairs passive avoidance learning and sensorimotor gating in rats.

Authors:  Samuel B Gutherz; Catherine V Kulick; Colin Soper; Alexei Kondratyev; Karen Gale; Patrick A Forcelli
Journal:  Epilepsy Behav       Date:  2014-08-12       Impact factor: 2.937

2.  Efficacy of antiepileptic drugs in neonatal seizures: a systematic review protocol.

Authors:  Yang He; Jun Tang; Meng Zhang; Tao Xiong; Shalini Ojha; Imti Choonara; Dezhi Mu
Journal:  BMJ Paediatr Open       Date:  2020-06-29

Review 3.  What is the Best Predictor of Phenobarbital Pharmacokinetics to Use for Initial Dosing in Neonates?

Authors:  Martin Šíma; Danica Michaličková; Ondřej Slanař
Journal:  Pharmaceutics       Date:  2021-02-25       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.